--- title: "U.S. Stock Market Midday Update: MDxHealth up 13.28%: Financing eliminates debt, raises sales guidance boosting confidence" type: "News" locale: "en" url: "https://longbridge.com/en/news/296134320.md" description: "MDxHealth SA rose 13.28%; Argenx rose 16.30%, with a transaction volume of 430 million USD; Amgen rose 0.20%, with a transaction volume of 345 million USD; AbbVie rose 0.11%, with a transaction volume of 340 million USD; Gilead Sciences rose 0.22%, with a market value of 171.9 billion USD" datetime: "2026-08-17T17:48:05.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296134320.md) - [en](https://longbridge.com/en/news/296134320.md) - [zh-HK](https://longbridge.com/zh-HK/news/296134320.md) generator: "portal-rs" --- # U.S. Stock Market Midday Update: MDxHealth up 13.28%: Financing eliminates debt, raises sales guidance boosting confidence **U.S. Stock Market Midday Update** MDxHealth SA rose by 13.28%. Based on recent key news: 1. On August 15, MDxHealth raised $20 million through a registered direct financing, eliminating a $10.4 million contingent liability to Novitas, strengthening its balance sheet and cash position. This move boosted investor confidence and drove the stock price up. 2. On August 15, MDxHealth reaffirmed its 2026 sales guidance of $110 million to $115 million, exceeding the market expectation of $98.814 million, with an anticipated year-on-year growth of 20-26%. This optimistic sales outlook further stimulated the rise in stock price. 3. On August 15, analyst Lake Street maintained a buy rating on MDxHealth, reflecting market confidence in the company's future growth, supporting the stock price increase. There are clear signs of industry recovery, with increased capital inflow. **Top Stocks by Trading Volume in the Industry** Argenx rose by 16.30%. Based on recent key news: 1. On August 17, Argenx announced positive results from its drug Efgartigimod in a Phase III trial for autoimmune myositis. The drug achieved its primary endpoint at week 52, showing significant clinical improvement compared to placebo, driving the stock price up. Source: Reuters 2. On August 17, Argenx's stock price rose over 14% during the session, reaching an all-time high. Analysts expect peak sales for the drug in the fields of immune-mediated necrotizing myopathy and dermatomyositis to reach $3 billion and $1.7 billion, respectively. Source: Zhitong Finance 3. On August 17, Argenx reported breakthrough progress with its drug Vyvgart in treating patients with inflammatory diseases, representing a market opportunity worth millions of dollars, attracting investor interest. Source: CNBC The biopharmaceutical industry has recently performed strongly, with investors focusing on new drug development progress. Amgen rose by 0.20%. Based on recent key news: 1. On August 17, Barclays raised Amgen's target price from $360 to $380, maintaining a neutral rating. This move indicates analysts' cautiously optimistic attitude towards Amgen's future performance, leading to a slight increase in stock price. 2. On August 17, market analysis showed that Amgen failed to make the top five stocks recommended by leading analysts. Nevertheless, Amgen still maintains a hold rating, indicating some uncertainty in the market regarding its future performance. 3. On August 17, the global pharmaceutical industry is undergoing restructuring, with Amgen as one of the industry giants. Its interim report reflects the company's competitiveness in areas such as immunology and oncology, further influencing investor confidence in its stock. Competition in the pharmaceutical industry is intensifying amid market restructuring AbbVie rose 0.11%, with increased trading volume. Based on recent key news: 4. On August 15, Glenview Capital Management increased its stake in AbbVie, showing confidence in the company, which may drive the stock price up. According to the latest 13F filing, Glenview Capital Management's holdings in AbbVie increased to approximately 149,000 shares. 5. On August 17, market analysis showed that although AbbVie was rated as "moderate buy," top analysts were more optimistic about five other stocks, which may limit AbbVie's upside potential. MarketBeat pointed out that AbbVie was not included in the list of the top five stocks recommended by top analysts. 6. On August 17, AbbVie was reported to have new blockbuster business, which may boost market expectations for its future growth. The pharmaceutical industry is undergoing a market capitalization restructuring, with increasing competition. **Stocks ranked at the top of the industry by market capitalization** Gilead Sciences rose 0.22%, with a market capitalization reaching $171.9 billion, and increased trading volume, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation ### Related Stocks - [MDXH.US](https://longbridge.com/en/quote/MDXH.US.md) - [ARGX.US](https://longbridge.com/en/quote/ARGX.US.md) - [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md) - [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md) - [GILD.US](https://longbridge.com/en/quote/GILD.US.md) ## Related News & Research - [Ross Stores To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday](https://longbridge.com/en/news/296618142.md) - [BioCryst Pharmaceuticals (BCRX), What Is Behind The Fresh Attention Now?](https://longbridge.com/en/news/296688974.md) - [Prediction: This Is Where Pfizer Stock Will Be in 2030](https://longbridge.com/en/news/296683959.md) - [GSK scores regulatory wins for chronic hepatitis B drug, cancer therapy](https://longbridge.com/en/news/296748151.md) - [JAGX: Q2 2026 revenue fell 60% year-over-year as focus shifted to rare disease drug development](https://longbridge.com/en/news/296396312.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**